Insulin Degludec Injection, Solution
NDC Package 73070-403-15
Package Information
Insulin Degludec injection is insulin Degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.Limitations of Use•Not recommended for the treatment of diabetic ketoacidosis. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk Pharma, Inc., this product is identified by NDC 73070-403 and is authorized under FDA application BLA203314.
Identification & Billing
- RxCUI: 1670011 - insulin degludec 100 UNT/ML in 3 ML Pen Injector
- RxCUI: 1670011 - 3 ML insulin degludec 100 UNT/ML Pen Injector
- RxCUI: 1670011 - insulin degludec 100 UNT/ML per 3 ML Pen Injector
- RxCUI: 1670021 - insulin degludec 200 UNT/ML in 3 ML Pen Injector
- RxCUI: 1670021 - 3 ML insulin degludec 200 UNT/ML Pen Injector
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 73070 - Novo Nordisk Pharma, Inc.
- 73070-403 - Insulin Degludec
- 73070-403-15 - 5 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC
- 73070-403 - Insulin Degludec
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 73070-403-15 identifies a specific commercial package of 5 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic of Insulin Degludec, a human prescription drug labeled by Novo Nordisk Pharma, Inc.. This injection, solution is formulated for subcutaneous use and contains insulin degludec as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk Pharma, Inc. on July 01, 2022.
How is this Novo Nordisk Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 73070040315. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 15 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.